Context Therapeutics (CNTX) Short Interest Ratio & Short Volume $1.51 -0.05 (-3.21%) (As of 11:48 AM ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Context Therapeutics Short Interest DataContext Therapeutics (CNTX) has a short interest of 879,600 shares, representing 1.49% of the float (the number of shares available for trading by the public). This marks a -13.76% decrease in short interest from the previous month. The short interest ratio (days to cover) is 3.2, indicating that it would take 3.2 days of the average trading volume of 303,145 shares to cover all short positions.Current Short Interest879,600 sharesPrevious Short Interest1,020,000 sharesChange Vs. Previous Month-13.76%Dollar Volume Sold Short$1.62 millionShort Interest Ratio3.2 Days to CoverLast Record DateNovember 15, 2024Outstanding Shares75,000,000 sharesFloat Size59,220,000 sharesShort Percent of Float1.49%Today's Trading Volume60,905 sharesAverage Trading Volume303,145 sharesToday's Volume Vs. Average20% Short Selling Context Therapeutics? Sign up to receive the latest short interest report for Context Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCNTX Short Interest Over TimeCNTX Days to Cover Over TimeCNTX Percentage of Float Shorted Over Time Ad Porter & CompanyThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. Context Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 11/15/2024879,600 shares $1.62 million -13.8%1.5%3.2 $1.84 10/31/20241,020,000 shares $2.22 million -1.0%1.7%4.1 $2.18 10/15/20241,030,000 shares $2.01 million -5.5%1.7%4.7 $1.95 9/30/20241,090,000 shares $2.14 million -35.5%1.8%6 $1.96 9/15/20241,690,000 shares $3.53 million -4.5%2.9%8 $2.09 8/31/20241,770,000 shares $4.35 million -4.8%3.0%7.7 $2.46 Get the Latest News and Ratings for CNTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/15/20241,860,000 shares $4.95 million -7.9%3.1%7.7 $2.66 7/31/20242,020,000 shares $4.36 million -1.9%3.1%7.2 $2.16 7/15/20242,060,000 shares $4.53 million -7.6%3.1%2.9 $2.20 6/30/20242,230,000 shares $4.47 million +99.1%3.4%3.2 $2.01 6/15/20241,120,000 shares $2.20 million -15.2%1.7%1.6 $1.96 5/31/20241,320,000 shares $2.61 million +30.7%2.0%2.3 $1.98 5/15/20241,010,000 shares $1.71 million +15,438.5%1.4%1.8 $1.69 4/30/20246,500 shares $8,645.00 -83.9%0.1%0 $1.33 4/15/202440,400 shares $61,004.00 +260.7%0.3%0.7 $1.51 3/31/202411,200 shares $15,456.00 -34.1%0.1%0.2 $1.38 3/15/202417,000 shares $18,530.00 +57.4%0.1%0.3 $1.09 2/29/202410,800 shares $12,312.00 -60.0%0.1%0.2 $1.14 2/15/202427,000 shares $27,540.00 -3.2%0.2%0.6 $1.02 1/31/202427,900 shares $28,458.00 -14.9%0.2%0.7 $1.02 1/15/202432,800 shares $39,032.00 +70.8%0.2%0.8 $1.19 12/31/202319,200 shares $21,696.00 -37.9%0.1%0.4 $1.13 12/15/202330,900 shares $30,282.00 +37.3%0.2%0.7 $0.98 11/30/202322,500 shares $19,125.00 -37.2%0.2%0.6 $0.85 11/15/202335,800 shares $36,337.00 -28.7%0.3%1 $1.02 10/31/202350,200 shares $53,212.00 +11.8%0.4%1.4 $1.06 10/15/202344,900 shares $57,921.00 +14.5%0.3%1.2 $1.29 9/30/202339,200 shares $59,192.00 +184.1%0.3%1 $1.51 9/15/202313,800 shares $13,319.76 +97.1%0.1%0.3 $0.97 8/31/20237,000 shares $7,210.00 No Change0.1%0.1 $1.03 8/15/20237,000 shares $8,540.00 -25.5%0.1%0.1 $1.22 7/31/20239,400 shares $10,340.00 -86.9%0.1%0.1 $1.10 7/15/202371,600 shares $85,920.00 -52.2%0.5%0.5 $1.20 6/30/2023149,900 shares $239,840.00 +30.4%1.0%0.9 $1.60 6/15/2023115,000 shares $140,300.00 -54.6%0.8%0.7 $1.22 5/31/2023253,300 shares $220,371.00 +153.3%1.7%1.5 $0.87 5/15/2023100,000 shares $49,310.00 -15.6%0.7%1 $0.49 4/30/2023118,500 shares $68,860.35 +6.8%0.9%1 $0.58 4/15/2023111,000 shares $69,352.80 +19.5%0.8%0.1 $0.62 3/31/202392,900 shares $52,228.38 -54.6%0.7%0 $0.56This company will win the AI race (Ad)Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. 3/15/2023204,800 shares $141,619.20 +33.9%1.5%0.1 $0.69 2/28/2023152,900 shares $117,733.00 -27.2%1.1%0.1 $0.77 2/15/2023210,100 shares $175,475.52 -53.7%1.6%0.1 $0.84 1/31/2023453,800 shares $481,028.00 -25.1%3.3%0.2 $1.06 1/15/2023605,500 shares $443,831.50 +676.3%4.4%0.9 $0.73 12/30/202278,000 shares $50,832.60 -7.9%0.6%0.1 $0.65 12/15/202284,700 shares $55,902.00 -53.2%0.6%0.6 $0.66 11/30/2022181,100 shares $249,918.00 +11.2%1.3%0.9 $1.38 11/15/2022162,800 shares $195,360.00 -29.6%1.2%0.8 $1.20 10/31/2022231,300 shares $291,438.00 +616.1%1.7%0.8 $1.26 10/15/202232,300 shares $35,207.00 -74.3%0.2%0.1 $1.09 9/30/2022125,500 shares $139,305.00 +119.4%0.9%0.4 $1.11 9/15/202257,200 shares $92,664.00 -58.0%0.4%0.2 $1.62 8/31/2022136,300 shares $258,970.00 +48.6%1.0%0.4 $1.90 8/15/202291,700 shares $182,483.00 -26.2%0.7%0.2 $1.99 7/31/2022124,200 shares $234,725.58 -34.8%0.9%0.3 $1.89 7/15/2022190,600 shares $373,576.00 -22.7%1.4%0.6 $1.96 6/30/2022246,700 shares $523,004.00 -10.2%1.8%0.7 $2.12 6/15/2022274,800 shares $585,324.00 +202.0%2.0%0.7 $2.13 5/31/202291,000 shares $203,840.00 +104.0%0.7%0.2 $2.24 5/15/202244,600 shares $64,670.00 +216.3%0.3%0.2 $1.45 4/30/202214,100 shares $20,445.00 -55.1%0.1%0 $1.45 4/15/202231,400 shares $56,520.00 -53.9%0.2%0.1 $1.80 3/31/202268,100 shares $147,777.00 -53.4%0.5%0.2 $2.17 3/15/2022146,000 shares $261,340.00 +129.2%1.1%0.2 $1.79 2/28/202263,700 shares $119,756.00 -48.2%0.5%0 $1.88 2/15/2022122,900 shares $251,945.00 +38.7%0.9%0 $2.05 1/31/202288,600 shares $180,744.00 -11.3%0.6%0 $2.04 1/15/202299,900 shares $224,775.00 -86.7%0.7%0 $2.25 12/31/2021749,000 shares $1.99 million No Change5.8%0.1 $2.66 CNTX Short Interest - Frequently Asked Questions What is Context Therapeutics' current short interest? Short interest is the volume of Context Therapeutics shares that have been sold short but have not yet been covered or closed out. As of November 15th, investors have sold 879,600 shares of CNTX short. 1.49% of Context Therapeutics' shares are currently sold short. Learn More on Context Therapeutics' current short interest. What is a good short interest ratio for Context Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CNTX shares currently have a short interest ratio of 3.0. Learn More on Context Therapeutics's short interest ratio. What is a good short interest percentage for Context Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.49% of Context Therapeutics' floating shares are currently sold short. Is Context Therapeutics' short interest increasing or decreasing? Context Therapeutics saw a decrease in short interest in November. As of November 15th, there was short interest totaling 879,600 shares, a decrease of 13.8% from the previous total of 1,020,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Context Therapeutics' float size? Context Therapeutics currently has issued a total of 75,000,000 shares. Some of Context Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Context Therapeutics currently has a public float of 59,220,000 shares. How does Context Therapeutics' short interest compare to its competitors? 1.49% of Context Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Context Therapeutics: Acelyrin, Inc. (7.89%), Korro Bio, Inc. (4.42%), Aquestive Therapeutics, Inc. (10.93%), Akebia Therapeutics, Inc. (5.48%), Aura Biosciences, Inc. (2.22%), Foghorn Therapeutics Inc. (3.52%), Canopy Growth Co. (10.02%), KalVista Pharmaceuticals, Inc. (17.05%), GH Research PLC (6.50%), Tango Therapeutics, Inc. (14.40%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($4.85 billion), Charter Communications, Inc. ($4.81 billion), International Paper ($2.96 billion), Cencora, Inc. ($2.40 billion), Paychex, Inc. ($2.38 billion), Lululemon Athletica Inc. ($2.05 billion), SoFi Technologies, Inc. ($2.03 billion), Live Nation Entertainment, Inc. ($1.93 billion), Onsemi ($1.82 billion), and Tractor Supply ($1.65 billion). View all of the most shorted stocks. What does it mean to sell short Context Therapeutics stock? Short selling CNTX is an investing strategy that aims to generate trading profit from Context Therapeutics as its price is falling. CNTX shares are trading down $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Context Therapeutics? A short squeeze for Context Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CNTX, which in turn drives the price of the stock up even further. How often is Context Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CNTX, twice per month. The most recent reporting period available is November, 15 2024. More Short Interest Resources from MarketBeat Related Companies SLRN Short Squeeze KRRO Short Squeeze AQST Short Squeeze AKBA Short Squeeze AURA Short Squeeze FHTX Short Squeeze CGC Short Squeeze KALV Short Squeeze GHRS Short Squeeze TNGX Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CNTX) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
